Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:190 |
|---|---|
| Enthalten in: |
British journal of haematology - 190(2020), 1 vom: 01. Juli, Seite e11-e13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Griffin, Daniel O [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.07.2020 Date Revised 18.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.16792 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309574382 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309574382 | ||
| 003 | DE-627 | ||
| 005 | 20231225134216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.16792 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309574382 | ||
| 035 | |a (NLM)32374029 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Griffin, Daniel O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.07.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a hypercoagulability | |
| 650 | 4 | |a pulmonary embolism | |
| 650 | 4 | |a thromboembolic | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Methylprednisolone |2 NLM | |
| 650 | 7 | |a X4W7ZR7023 |2 NLM | |
| 700 | 1 | |a Jensen, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Mushmoom |e verfasserin |4 aut | |
| 700 | 1 | |a Chin, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Chin, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Parnell, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Awwad, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Darshan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 190(2020), 1 vom: 01. Juli, Seite e11-e13 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:190 |g year:2020 |g number:1 |g day:01 |g month:07 |g pages:e11-e13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.16792 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 190 |j 2020 |e 1 |b 01 |c 07 |h e11-e13 | ||